SG Americas Securities LLC acquired a new position in shares of Evolent Health Inc (NYSE:EVH) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,756 shares of the technology company’s stock, valued at approximately $156,000.
Several other hedge funds have also recently bought and sold shares of EVH. ETF Managers Group LLC acquired a new position in shares of Evolent Health during the second quarter worth about $102,000. BNP Paribas Arbitrage SA boosted its position in shares of Evolent Health by 815.4% during the second quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock worth $120,000 after buying an additional 4,232 shares during the period. IPG Investment Advisors LLC acquired a new position in shares of Evolent Health during the third quarter worth about $195,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Evolent Health during the third quarter worth about $205,000. Finally, Royal Bank of Canada raised its holdings in Evolent Health by 1,197.8% during the second quarter. Royal Bank of Canada now owns 8,293 shares of the technology company’s stock worth $210,000 after acquiring an additional 7,654 shares in the last quarter. 95.38% of the stock is owned by institutional investors.
Shares of Evolent Health Inc (EVH) opened at $13.45 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.34 and a quick ratio of 3.34. The stock has a market capitalization of $1,040.00 and a P/E ratio of -11.80. Evolent Health Inc has a 52 week low of $10.30 and a 52 week high of $27.50.
Several analysts recently issued reports on EVH shares. Leerink Swann set a $25.00 target price on Evolent Health and gave the stock a “buy” rating in a report on Saturday, November 18th. Jefferies Group reiterated a “buy” rating and set a $28.00 target price on shares of Evolent Health in a report on Wednesday, September 6th. Cantor Fitzgerald reiterated a “buy” rating and set a $30.00 target price on shares of Evolent Health in a report on Thursday, November 2nd. SunTrust Banks reiterated a “buy” rating and set a $30.00 target price on shares of Evolent Health in a report on Friday, November 3rd. Finally, KeyCorp started coverage on Evolent Health in a report on Tuesday, September 19th. They set an “overweight” rating and a $23.00 target price on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $28.00.
ILLEGAL ACTIVITY WARNING: This article was reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.com-unik.info/2017/12/27/sg-americas-securities-llc-invests-156000-in-evolent-health-inc-evh-stock.html.
Evolent Health Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.